Navigation Links
Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
Date:12/18/2007

EAST SETAUKET, N.Y., Dec. 18 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) a developer of improved methods for both detection and treatment of cancer, announced the closing of a private placement. In the placement, Lixte sold 1,000,000 shares of its Common Stock at a price of $0.65 per share resulting in gross proceeds of $650,000. WestPark Capital, Inc. acted as placement agent and received $65,000 in commissions and $26,000 representing a non-accountable expense fee. Lixte also issued to WestPark five year warrants to purchase up to 100,000 shares of the Company's Common Stock and five year incentive warrants to purchase up to an additional 20,000 shares, all such warrants to be exercisable at $0.65 per share.

Lixte agreed to file a registration statement with the SEC covering resale of the shares upon written request from holders who represent at least 50% of the shares. Lixte also granted to the holders piggyback registration rights.

John Kovach, Lixte's President, stated that Lixte intends to use the net proceeds to pursue development of proprietary compounds for the submission of an IND to the Food & Drug Administration for a Phase I clinical trial, and for working capital.

The offer and sale of the shares sold were not registered under the Securities Act of 1933, as amended in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act and Regulation D promulgated thereunder. The shares sold by Lixte may not be reoffered or sold in the United States by the holders in the absence of an effective registration statement, or exemption from the registration requirements, under the Securities Act.

About Lixte

Lixte is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, the Company develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire/ -- According to Millennium Research Gr...ogy market intelligence, the nearly $3 billion US ...o see rapid growth over the next five years despit...for Trauma Devices 2010 report finds that this ...ve years, with competitors introducing specialized...
(Date:11/25/2009)...nd JOHANNESBURG, November 25 ,iThem...covery announced today,that they have signed a col...ies, services. , Pyxis,s world class comp...ill be coupled with iThemba,s service division to ...to projects identified through Pyxis,internationa...
(Date:11/24/2009)...wire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX ...aortic disorders, announced today that it has file... in, the patent infringement lawsuit brought again...s filed in the United States District Court in Ind...that the stay remain in effect while the United St...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 12991 1First Catalog Cancer Biochip for Sequence Capture Now Available from febit 12991 2Elsevier launches official version of BrainNavigator 51462 1Elsevier launches official version of BrainNavigator 51462 2Mystery E coli genes essential for survival of many species 9234 1Mystery E coli genes essential for survival of many species 9234 2
...INESS WIRE)--Mar 26, 2007 - Study results show,tha... (Lp-PLA2), a,cardiovascular-specific inflammatory...ead to heart attack and stroke, is,especially pred...metabolic syndrome--a serious medical condition th...s, which were presented yesterday,at the American ...
...ch 26, 2007 /PRNewswire/ -- Cleveland Clinic,resea...pite raising,high density lipoprotein cholesterol ...did not slow the progression of,plaque buildup in ...und probe. , Steven Nissen, M.D., Chairman of Card...nvestigator of this clinical trial, will,present t...
Other Medicine Technology:Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 2Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 2Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 4
(Date:11/27/2009)...t manufacturers who use medical load cells at the ...lars by bringing in technology partner Flintec ear...o-active medical manufacturers are calling in Flin...r projects, ensuring that progress will not be con...ly outdated technology. , ...
(Date:11/26/2009)...athiomolybdate (TM) has been shown in studies to b...disease caused by an overload of copper, and certa...ttle, however, is known about how the drug works a...hwestern University researchers now has provided a... of TM bound to copper-loaded metallochaperones. T...
(Date:11/26/2009)...Triangle Dental (RTDental), a leading dental group...ed the expansion of its services to include LUMINE...illan. , Durham, NC (P...nounce that Dr. Doug Macmillan, an experienced LU... advanced training seminar. RTDental’s abil...
(Date:11/25/2009)...ov. 25 Onyx Pharmaceut...the company will host two investor events in Decem...009 - 9:00 a.m. CT/10:00 a.m. ET ,, Principal...rounding carfilzomib in relapsed and/or refractory...n Society of Hematology (ASH) Annual Meeting and E...
(Date:11/25/2009)... The Black AIDS Institut...ermine executive leadership for 2010. ,, The ne...ers with specialties in public policy, law, financ...ness entrepreneurship. The Board also comes from a... heterosexual and gay Black men and women, some li...
Breaking Medicine News(10 mins):Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...nth of illegal abortions, said she will not contes...uth Wales (NSW) Medical// Tribunal. Suman So..., according to the Sydney Morning Herald newspaper...ounsel Mr Phillip Boulten and Mr Michael Fordham's...
...en’s Research Hospital has announced that improvem...r medulloblastoma have// significantly increased t... The treatment increased the overall five-ye... the 48 high-risk patients from 55 percent to 70 p...
People who have a low response to alcohol or the so called ability to
...may no longer be included in the specialist catego...omes into force//. A few radiologists who h...sicians understand the benefits of having them as ...st clinics. And the few who do get in just have to...
...a and dengue fever in the state has been brought o...s aegypti, mosquito is the common carrier of both .... Hence, the state has taken up an integrated mosq.... Padmanabhan, Director of Public Health and Preve...
... proteins in the eye is the main trigger for the u...searchers at Case Western Reserve University and t...lled blood vessel growth is one of the main reason... Salomon and his graduate students Kutralanathan R...
Other Medicine News:Health News:Improved Treatment Raises Medulloblastoma Survival Rate 2Health News:Molecule responsible for age associated macular degeneration identified 2
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...lizer achieves optimum lung penetration for maximu...ze range is 1.04-1.10 µ at 6-8 LPM. Latex-fr...t., ,As the world leader in airway management pro...rance of proven technology by offering top brands ...
...lizer achieves optimum lung penetration for maximu...ze range is 1.04-1.10 µ at 6-8 LPM. Latex-fr...t., ,As the world leader in airway management pro...rance of proven technology by offering top brands ...
Medicine Products: